Artelo Biosciences, a clinical-stage pharmaceutical company specializing in modulating lipid-signaling pathways, has recently published new pre-clinical research demonstrating the effectiveness of its asset, ART26.12, in treating and preventing Oxaliplatin-Induced Peripheral Neuropathy (OIPN). This ground-breaking discovery has significant implications for individuals living with cancer, pain, and neurological conditions. The findings shed light on a potential novel inhibitor, ART26.12, that could revolutionize the management of OIPN.
Artelo Biosciences, a San Diego-based clinical-stage pharmaceutical company, has unveiled a new research article
Comments